Results 321 to 330 of about 123,600 (352)
Some of the next articles are maybe not open access.

Myelodysplastic syndromes

The Lancet, 2014
Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid leukaemia in a third of patients. 15% of cases occur after chemotherapy or radiotherapy for a previous cancer; the syndromes are most common in elderly people.
Lionel, Adès   +2 more
openaire   +2 more sources

Thrombocytosis in myelodysplastic and myelodysplastic/myeloproliferative syndromes

Leukemia & Lymphoma, 2007
Thrombocytosis at diagnosis is uncommon in myelodysplastic (MDS) and myelodysplastic/myeloproliferative (MDS/MPD) syndromes. We conducted a retrospective analysis to determine the clinical and haematopathological features of such patients, and the effect of thrombocytosis on prognosis.
Dhatri, Kodali   +4 more
openaire   +2 more sources

Hypoplastic myelodysplastic syndrome

Cancer, 1988
Over a period of 8 years 11 of 64 patients seen at Loyola University Medical Center with the diagnosis of myelodysplastic syndrome (MDS) also exhibited bone marrow hypoplasia (marrow cellularity of 25% or less) at presentation. The other 53 had normocellular or hypercellular marrow.
S, Nand, J E, Godwin
openaire   +2 more sources

Myelodysplastic syndromes

Blood, 2008
AbstractThere has been a remarkable explosion of knowledge into the molecular defects that underlie the acute and chronic leukemias, leading to the introduction of targeted therapies that can block key cellular events essential for the viability of the leukemic cell.
openaire   +2 more sources

Myelodysplastic Syndromes

New England Journal of Medicine, 2020
Tatiana, Raskovalova   +2 more
openaire   +4 more sources

The Myelodysplastic Syndromes

Hematology/Oncology Clinics of North America, 2009
Myelodysplastic syndromes (MDS) are a heterogeneous group of bone marrow disorders that affect mostly the elderly and have a variable probability of progression to acute leukemia. The diagnosis of MDS rests largely on a critical morphologic review of blood and bone marrow slides, with careful correlation with other clinical and essential laboratory ...
openaire   +2 more sources

Pharmacotherapy of myelodysplastic syndromes

Expert Opinion on Pharmacotherapy, 2010
Despite the remarkable progress in the treatment of patients with myelodysplastic syndromes (MDS) in the past decade, response to the hypomethylating agents azacitidine and decitabine in non-del(5q) MDS patients remains at approximately 50%, leaving half of patients needing treatment with essentially no options.
Naomi, Galili, Azra, Raza
openaire   +2 more sources

Oncogenes in the myelodysplastic syndrome

Blood Reviews, 1989
The conversion of normal haemopoietic stem cells to myelodysplastic and then to leukaemic cells is marked by a number of events leading to progressive genetic changes in the abnormal clonal population. Cytogenetic evidence points to abnormalities at specific chromosomal locations, commonly involving chromosomes 5 and 7, where there are a particular ...
openaire   +2 more sources

Germline variants drive myelodysplastic syndrome in young adults

Leukemia, 2021
Simone Feurstein   +2 more
exaly  

Myelodysplastic Syndromes

Scottish Medical Journal, 1994
P G, Cachia, R A, Padua
openaire   +2 more sources

Home - About - Disclaimer - Privacy